bioAffinity Technologies (BIAF) Registration filing summary
Event summary combining transcript, slides, and related documents.
Registration filing summary
16 Jun, 2026Offering details and pricing
Registered securities include common stock and pre-funded warrants, with shares and warrants to be sold directly to investors through a placement agent on a best-efforts basis.
Purchase price per share and per pre-funded warrant is set, with pre-funded warrants exercisable at $0.007 per share.
Placement Agent receives a 7.5% cash fee on gross proceeds and 3% of shares sold as warrants.
The offering is subject to market conditions and may be closed in one or more tranches.
No guarantee of successful placement; the company retains the right to accept or reject offers.
Underwriters and syndicate
WallachBeth Capital LLC acts as exclusive placement agent, with the ability to retain sub-agents or selected dealers.
Placement Agent is not obligated to underwrite or purchase securities for its own account.
Placement Agent receives expense reimbursement up to $120,000.
Placement Agent Warrants are subject to transfer restrictions for 180 days post-offering.
Risk factors and disclosures
The company provides indemnification to the Placement Agent for liabilities except in cases of negligence or willful misconduct.
No conflicts of interest with FINRA members are disclosed; compliance with FINRA rules is affirmed.
The company is not required to register as an investment company after the offering.
Latest events from bioAffinity Technologies
- Q2 2026 saw 216% CyPath® Lung test growth and 19% revenue increase, but liquidity risks remain.BIAF
Q2 2026 - Noninvasive lung cancer diagnostic sees growth, but ongoing capital needs and risks remain.BIAF
Registration filing - CyPath Lung streamlines nodule risk assessment, reducing unnecessary biopsies and patient anxiety.BIAF
Status update - CyPath® Lung revenue surged, but losses widened and liquidity concerns remain.BIAF
Q1 2026 - AI-powered lung diagnostics firm registers 497,483 shares for resale; proceeds depend on warrant exercises.BIAF
Registration filing - AI-powered CyPath Lung enables accurate, noninvasive early lung cancer detection and market growth.BIAF
Investor presentation - Proxy seeks approval for director elections, equity plan changes, and a reverse stock split.BIAF
Proxy Filing - CyPath® Lung test sales surged 99% in 2025, driving record revenue and future growth momentum.BIAF
Q4 2025 - Ten key proposals, including equity plan expansion and reverse stock split, recommended for approval.BIAF
Proxy Filing